◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › K › KMDA

Kamada (KMDA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-10-02

Kamada (KMDA) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Rehovot, Israel with about 462 employees. Its market capitalization is roughly $444 million. In the fiscal year ended 2025-12-31, KMDA reported $180M in revenue and $20M in net income.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Interactive charts & full statements → Open the KMDA valuation workbench →

KMDA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Revenue	$192M	$180M	$161M	$143M	$129M	$104M	$133M	$127M	$114M	$103M	$77M	$70M	$72M	$71M	$73M	$56M	$36M	$15M	$15M	$13M
Gross Profit	$78M	$76M	$70M	$55M	$47M	$30M	$48M	$50M	$41M	$32M	$22M	$16M	$16M	$26M	$23M	$16M	$6M	($1M)	$0M	$3M
Gross Margin %	40.8%	42.3%	43.5%	38.9%	36.1%	29.3%	35.7%	39.1%	36.2%	31.2%	27.9%	22.8%	21.7%	37.4%	31.2%	28.1%	16.7%	-5.7%	0.5%	23.5%
Operating Income (EBIT)	$28M	$26M	$20M	$10M	$5M	($1M)	$19M	$23M	$19M	$7M	($6M)	($11M)	($11M)	$4M	$4M	($2M)	($11M)	($16M)	($17M)	($16M)
Operating Margin %	14.5%	14.5%	12.5%	7.1%	3.5%	-0.7%	14.4%	17.9%	16.8%	7.2%	-7.5%	-16.3%	-15.2%	5.2%	5.8%	-4.1%	-29.6%	-109.3%	-112.0%	-121.4%
Net Income	$22M	$20M	$14M	$8M	($2M)	($2M)	$17M	$22M	$22M	$7M	($7M)	($11M)	($13M)	$0M	$0M	($3M)	($15M)	($22M)	($12M)	($23M)
Net Margin %	11.6%	11.2%	9.0%	5.8%	-1.8%	-2.1%	12.9%	17.5%	19.5%	6.7%	-8.7%	-16.1%	-17.6%	0.6%	0.4%	-6.2%	-41.8%	-147.1%	-81.8%	-170.4%
EBITDA	$42M	$39M	$28M	$21M	$11M	$4M	$25M	$28M	$23M	$11M	($2M)	($7M)	($8M)	$8M	$7M	$3M	($9M)	($16M)	($15M)	($20M)
Earnings Per Share (EPS)	$0.38	$0.35	$0.25	$0.15	$-0.05	$-0.05	$0.38	$0.55	$0.55	$0.18	$-0.18	$-0.31	$-0.35	$0.01	$0.01	$-0.13	$-0.61	$-0.88	$-0.94	$-2.16
Shares Outstanding (M)	58M	58M	58M	54M	45M	45M	45M	41M	41M	38M	36M	36M	36M	33M	29M	28M	25M	25M	13M	11M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KMDA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$55M	$45M	$45M	$47M	$45M	$44M	$39M	$42M
Gross Profit	$22M	$19M	$17M	$20M	$19M	$21M	$17M	$17M
Gross Margin %	40.9%	42.2%	38.0%	42.0%	42.3%	47.1%	43.7%	41.3%
Operating Income (EBIT)	$10M	$7M	$4M	$8M	$7M	$8M	$5M	$5M
Operating Margin %	17.3%	15.4%	8.0%	16.6%	15.8%	17.7%	13.0%	12.7%
Net Income	$9M	$4M	$4M	$5M	$7M	$4M	$4M	$4M
Net Margin %	16.9%	9.1%	8.0%	11.3%	16.5%	9.0%	9.8%	9.2%
EBITDA	$13M	$9M	$9M	$10M	$10M	$10M	$7M	$7M
Earnings Per Share (EPS)	$0.16	$0.07	$0.06	$0.09	$0.13	$0.07	$0.07	$0.07
Shares Outstanding (M)	58M	59M	62M	59M	57M	57M	54M	55M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KMDA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Cash from Operations (CFO)	$36M	$28M	$48M	$4M	$29M	($9M)	$19M	$28M	$11M	$4M	$2M	($14M)	($10M)	($4M)	($8M)	$1M	$11M	($13M)	($13M)	($13M)
Capital Expenditures (CapEx)	$10M	$11M	$11M	$6M	$4M	$4M	$5M	$2M	$3M	$4M	$3M	$3M	$3M	$6M	$5M	$2M	$4M	$5M	$4M	$8M
Free Cash Flow (FCF)	$26M	$17M	$37M	($2M)	$25M	($13M)	$14M	$26M	$8M	($1M)	($1M)	($17M)	($13M)	($9M)	($13M)	($1M)	$7M	($18M)	($16M)	($20M)
FCF Margin %	13.8%	9.4%	22.9%	-1.1%	19.2%	-12.6%	10.2%	20.5%	6.7%	-0.5%	-1.0%	-23.8%	-18.1%	-13.5%	-17.7%	-1.7%	18.7%	-122.6%	-108.1%	-150.3%
Dividends Paid	$15M	$12M	$0M	$0M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KMDA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$18M	$0M	$8M	$10M	$8M	($1M)	$10M	$22M
Capital Expenditures (CapEx)	$2M	$1M	$3M	$4M	$2M	$1M	$3M	$2M
Free Cash Flow (FCF)	$16M	($1M)	$5M	$7M	$6M	($2M)	$7M	$20M
FCF Margin %	29.1%	-2.8%	11.1%	14.5%	13.4%	-4.5%	19.2%	48.1%
Dividends Paid	$14M	$0M	$0M	$0M	$12M	$0M	—	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KMDA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$383M	$379M	$372M	$355M	$322M	$319M	$211M	$174M	$138M	$122M	$100M	$102M	$120M	$139M	$89M	$85M	$92M	$63M	$42M
Cash & Cash Equivalents	$29M	$75M	$78M	$56M	$34M	$19M	$70M	$43M	$18M	$13M	$10M	$5M	$15M	$59M	$17M	$24M	$26M	$30M	$13M
Total Liabilities	$114M	$110M	$113M	$111M	$146M	$142M	$32M	$38M	$26M	$33M	$33M	$29M	$39M	$49M	$61M	$63M	$65M	$33M	$29M
Total Debt (Short + Long-Term)	$2M	$2M	$2M	$1M	$18M	$21M	$1M	$2M	$1M	$2M	$2M	$0M	$8M	$16M	$24M	$23M	$0M	$0M	$1M
Total Shareholders' Equity	$270M	$269M	$259M	$244M	$176M	$177M	$179M	$135M	$112M	$89M	$67M	$73M	$81M	$90M	$28M	$23M	$26M	$30M	$13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KMDA viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

EVO · Evotec SE ADR — $551 million
AQST · Aquestive Therapeutics Inc — $487 million
EOLS · Evolus Inc — $487 million
TKNO · Alpha Teknova Inc — $454 million
TLRY · Tilray Inc — $392 million
CGC · Canopy Growth Corp — $293 million
BIOA · BioAge Labs, Inc — $269 million
GLAS · Glass House Brands Inc. — $221 million

← KMCSHIL All “K” companies KME →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.